Linagliptin Eg (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which enhance insulin secretion and suppress glucagon release in a glucose‑dependent manner, thereby lowering blood glucose.

The specific dose of Linagliptin Eg is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of linagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but has a distinct pharmacokinetic profile, allowing once‑daily dosing without dose adjustment in mild to moderate renal impairment, which can be an advantage over some alternatives.

Linagliptin Eg should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Linagliptin Eg is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptin Eg is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. It should also be avoided in individuals with a history of severe pancreatitis until the cause is clarified.